Related Experiment Videos
Oral alendronate in osteogenesis imperfecta
Edip Unal1, Ayhan Abaci, Ece Bober
1Department of Pediatrics, and Division of Endocrinology, Dokuz Eylul University, Faculty of Medicine, Inciralti-Izmir, Turkey.
Indian Pediatrics
|December 13, 2005
Summary
Oral alendronate effectively treated Osteogenesis Imperfecta (OI) in an eight-year-old boy, increasing bone density and reducing fractures. This demonstrates oral bisphosphonates as a viable, cost-effective alternative for OI management.
Area of Science:
- Pediatric Endocrinology
- Orthopedics
- Pharmacology
Background:
- Osteogenesis Imperfecta (OI) is a genetic disorder characterized by brittle bones, leading to frequent fractures.
- Management of OI often involves addressing bone fragility and fracture prevention.
Observation:
- An eight-year-old boy with OI presented with recurrent long bone fractures.
- The patient was treated with oral alendronate.
Findings:
- Oral alendronate treatment led to a significant increase in bone mineral density.
- A notable decrease in the number of fractures was observed during the treatment period.
Implications:
- Oral bisphosphonates, such as alendronate, offer an inexpensive and easily administered treatment option for selected OI cases.
- This case supports oral alendronate as a valuable alternative therapeutic strategy in the management of Osteogenesis Imperfecta.